PL441360A1 - Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych - Google Patents

Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych

Info

Publication number
PL441360A1
PL441360A1 PL441360A PL44136022A PL441360A1 PL 441360 A1 PL441360 A1 PL 441360A1 PL 441360 A PL441360 A PL 441360A PL 44136022 A PL44136022 A PL 44136022A PL 441360 A1 PL441360 A1 PL 441360A1
Authority
PL
Poland
Prior art keywords
estradiol
hydrogen peroxide
neurodegenerative diseases
concentration
metabolites
Prior art date
Application number
PL441360A
Other languages
English (en)
Inventor
Magdalena Górska-Ponikowska
Narcyz KNAP
Michał WOŹNIAK
Alicja KUBAN-JANKOWSKA
Jarosław Sławek
Paulina BASTIAN
Jarosław Dulski
Anna ROSZMANN
Tomasz BĄCZEK
Lucyna KONIECZNA
Mariusz BELKA
Dagmara Jacewicz
Joanna Drzeżdżon
Original Assignee
Gdański Uniwersytet Medyczny
Uniwersytet Gdański
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gdański Uniwersytet Medyczny, Uniwersytet Gdański filed Critical Gdański Uniwersytet Medyczny
Priority to PL441360A priority Critical patent/PL441360A1/pl
Priority to PCT/PL2023/050040 priority patent/WO2023234790A1/en
Priority to EP23816430.5A priority patent/EP4508436A4/en
Publication of PL441360A1 publication Critical patent/PL441360A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8827—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

Zgłoszenie dotyczy zastosowania nadtlenku wodoru i 17β-estradiolu oraz jego metabolitów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych, zwłaszcza choroby Parkinsona charakteryzującego się tym, że sposób diagnozowania chorób neurodegeneracyjnych obejmuje analizę poziomu nadtlenku wodoru oraz pochodnych 17β-estradiolu w surowicy krwi, po ich uprzednim wyizolowaniu z krwi pacjenta i przeprowadzeniu derywatyzacji chlorkiem dansylu, przy czym chorobę neurodegeneracyjną stwierdza się, kiedy stężenie nadtlenku wodoru w badanej próbce jest wyższe od stężenia oznaczonego dla zdrowej kontroli i kiedy w badanej próbce stężenie hydroksylowanych pochodnych 17β-estradiolu jest niższe, a stężenie metoksylowanych pochodnych17β-estradiolu jest wyższe względem stężeń oznaczanych dla zdrowej kontroli.
PL441360A 2022-06-02 2022-06-02 Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych PL441360A1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL441360A PL441360A1 (pl) 2022-06-02 2022-06-02 Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych
PCT/PL2023/050040 WO2023234790A1 (en) 2022-06-02 2023-05-29 APPLICATION OF HYDROGEN PEROXIDE AND 17β-ESTRADIOL AND ITS METABOLITES AS BIOMARKERS IN A METHOD OF DIAGNOSING NEURODEGENERATIVE DISEASES IN VITRO
EP23816430.5A EP4508436A4 (en) 2022-06-02 2023-05-29 APPLICATION OF HYDROGEN PEROXIDE AND 17ß-ESTRADIOL AND ITS METABOLITES AS BIOMARKERS IN A METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES IN VITRO

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441360A PL441360A1 (pl) 2022-06-02 2022-06-02 Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych

Publications (1)

Publication Number Publication Date
PL441360A1 true PL441360A1 (pl) 2023-12-04

Family

ID=89025328

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441360A PL441360A1 (pl) 2022-06-02 2022-06-02 Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych

Country Status (3)

Country Link
EP (1) EP4508436A4 (pl)
PL (1) PL441360A1 (pl)
WO (1) WO2023234790A1 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL450034A1 (pl) * 2024-10-15 2026-04-20 Gdański Uniwersytet Medyczny Zestaw biomarkerów oraz sposób diagnozowania in vitro nowotworu błony śluzowej trzonu macicy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0409176A2 (en) * 1989-07-17 1991-01-23 The Rockefeller University Method and materials for detecting pathology from alterations in estrogen metabolism
WO2005038453A1 (en) * 2003-10-17 2005-04-28 Medvet Science Pty Ltd Early assessment of motor recovery in spinal cord injury patients
WO2015161078A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of California Methods for comprehensive profiling of steroid metabolome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0409176A2 (en) * 1989-07-17 1991-01-23 The Rockefeller University Method and materials for detecting pathology from alterations in estrogen metabolism
WO2005038453A1 (en) * 2003-10-17 2005-04-28 Medvet Science Pty Ltd Early assessment of motor recovery in spinal cord injury patients
WO2015161078A1 (en) * 2014-04-17 2015-10-22 The Regents Of The University Of California Methods for comprehensive profiling of steroid metabolome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RIO, M.J.D., VELEZ-PARDO, C.: "Curr. Med. Chem. – Central Nervous System Agents, 2004, 4, 279-285", "THE HYDROGEN PEROXIDE AND ITS IMPORTANCE IN ALZHEIMER’S AND PARKINSON’S DISEASE" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL450034A1 (pl) * 2024-10-15 2026-04-20 Gdański Uniwersytet Medyczny Zestaw biomarkerów oraz sposób diagnozowania in vitro nowotworu błony śluzowej trzonu macicy

Also Published As

Publication number Publication date
WO2023234790A1 (en) 2023-12-07
EP4508436A1 (en) 2025-02-19
EP4508436A4 (en) 2025-08-13

Similar Documents

Publication Publication Date Title
Maggio et al. Associations among obesity, blood pressure, and left ventricular mass
Mirick et al. Melatonin as a biomarker of circadian dysregulation
Shirtcliff et al. Salivary cortisol results obtainable within minutes of sample collection correspond with traditional immunoassays
Alamdari et al. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein
Masika et al. Is measurement of TT3 by immunoassay reliable at low concentrations? A comparison of the Roche Cobas 6000 vs. LC–MSMS
Lamy et al. Assessment of tobacco, alcohol and cannabinoid metabolites in 645 meconium samples of newborns compared to maternal self-reports
Kivlighan et al. Blood contamination and the measurement of salivary progesterone and estradiol
PL441360A1 (pl) Zastosowanie nadtlenku wodoru oraz 17β-estradiolu i jego metabolitów jako biomarkerów w sposobie diagnozowania in vitro chorób neurodegeneracyjnych
Cui et al. Associations of exposure to per-and polyfluoroalkyl substances mixture with the numbers of lymph nodes in colorectal cancer patients
Mahmoud et al. Is inhibin B involved in the toxic effect of lead on male reproduction?
WO2009008511A1 (ja) 正常眼圧緑内障モデル及びそれを用いた被験物質の評価方法
du Plessis et al. The relationship of circulating homocysteine with fibrinogen, blood pressure, and other cardiovascular measures in African adolescents
Wu et al. Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases
Verburg et al. Prevalence of thyroid disorders in elderly people in Germany
Gierlich et al. Test-retest reliability of the acoustic voice quality index and the acoustic breathiness index
Hertweck et al. Ferriman-Gallwey scores, serum androgen and mullerian inhibiting substance levels in hirstute adolescent girls
Lee et al. Elevated blood pressure in children with cerebral palsy and its relationship with adiposity and physical activity
Moseby-Knappe et al. Biomarkers of brain injury after cardiac arrest; a statistical analysis plan from the TTM2 trial biobank investigators
Slob et al. The effect of acute noise exposure on the excretion of corticosteroids, adrenalin and noradrenalin in man
Leo et al. Modulation of red blood cell nitric oxide synthase phosphorylation in the quiescent and exercising human forearm
Abdulateef Correlation of serum prolactin with sleep duration, wake-up hour, and phases of the menstrual cycle in healthy adult subjects
Korkmaz et al. Serum prolidase levels in Graves’ disease without ophthalmopathy and its association with oxidative status
Diamandis et al. Effect of age on serum prostate-specific antigen in women
Gunnerbeck et al. Congenital Hypothyroidism and School Achievement in Adolescence: A Population-Based Sibling Control Study
Ertekin et al. Investigation of neopterin levels in children with Hashimoto thyroiditis